Benign prostat hiperplazisi ile ilişkili alt üriner sistem yakınmalarının tedavisinde tadalafil 5 mg’ın etkinliği

Kaynakça (4)

1. Gravas S, Bach T, Bachmann A, et al. EAU Guidelines on the Management of non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO) European Association of Urology 2015
2. Sairam K, Kulinskaya E, McNicholas TA, et al. Sildenafil influences lower urinary tract symptoms. BJU Int 2002;90:836–9
3. Mulhall JP, Guhring P, Parker M, Hopps C. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 2006;3:662–7. doi: 10.1111/j.1743-6109.2006.00259.x 4. Govorov A, Kasyan G, Priymak D, et al. Tadalafil in the management of lower urinary tract symptoms: a review of the literature and current practices in Russia. Cent European J Urol 2014;67:167–77. doi: 10.5173/ceju.2014.02.art10 5. Seftel AD, de la Rosette J, Birt J, et al. Coexisting lower urinary tract symptoms and erectile dysfunction: a systematic review of epidemiological data. Int J Clin Pract 2013;67:32–45. doi: 10.1111/ijcp.12044 6. Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003;44:637–49
4. Tinel H, Stelte-Ludwig B, Hütter J, Sandner P. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 2006;96:1259–63. doi: 10.1111/j.1464-410X.2006.06501.x 8. Filippi S, Morelli A, Sandner P, et al. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007;148:1019–29. doi: 10.1210/ en.2006-1079 9. Andersson KE, de Groat WC, McVary KT, et al. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn 2011;30:292–301. doi: 10.1002/nau.20999 10. Gacci M, Andersson KE, Chapple C, et al. Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Eur Urol 2016;70:124–33. doi: 10.1016/j. eururo.2015 11. Laydner HK, Oliveira P, Oliveira CR, et al. Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review. BJU Int 2010;107:1104– 9. doi: 10.1111/j.1464-410X.2010.09698.x 12. Liu L, Zheng S, Han P, Wei Q. Phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic